Matter No.: 14184-043001
Applicant(s): Mark G. Currie et al.
METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS

Figure 1. LCMS analysis of recombinant peptide variants

MM-416776

MD-915



Figure 1b: LCMS analysis of synthetic MD-1100 (Total Ion Chromatograph (TIC))



Figure 1c: LCMS analysis (Total Ion Chromatograph of blank used in MD-1100 analysis)



Figure 2. Chemically synthesized peptides in the Intestinal GC-C Receptor Activity Assay



Figure 3a. MM-416776 vs Zelnorm® in an acute Mouse Gastrointestinal Transit Model (GIT)

Matter No.: 14184-043001
Applicant(s): Mark G. Currie et al.
METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS



Figure 3b: MD-1100 vs. Zelnorm® in an acute Mouse Gastrointestinal Transit Model

Matter No.: 14184-043001
Applicant(s): Mark G. Currie et al.
METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS



Figure 4a. Purified MD-915 and MM-416776 in GIT Model



Figure 4b. Chemically Synthesized Peptides in GIT Model

Matter No.: 14184-043001
Applicant(s): Mark G. Currie et al.
METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS



Matter No.: 14184-043001
Applicant(s): Mark G. Currie et al.
METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS

Figure 4c. Chronic vs. Acute Dosing in GIT Assay



* p < 0.01
** p < 0.005
*** p < 0.0005

Figure 5a. MM-416776 vs Zelnorm® in a Mouse Intestinal Secretion Model



Figure 5b: MD-1100 vs Zelnorm® in Mouse Intestinal Secretion Model

Matter No.: 14184-043001
Applicant(s): Mark G. Currie et al.
METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS



Figure 6a. Recombinantly generated MD-915 and MM-416776 in Mouse Intestinal Secretion Model



Figure 6b. Chemically synthesized peptides in Mouse Intestinal Secretion Model

Matter No.: 14184-043001
Applicant(s): Mark G. Currie et al.
METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS



Matter No.: 14184-043001
Applicant(s): Mark G. Currie et al.
METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS

Figure 7: Effect of MD-1100 in a rat TNBS Colorectal Distention Assay



* p<0.05 as compared to "vehicle" value

Matter No.: 14184-043001
Applicant(s): Mark G. Currie et al.
METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS

Figure 8a: Visceral Antinociceptive Effects of MD-915 in a Mouse Writhing Assay



Figure 8b: Visceral Antinociceptive Effects of MD-1100 in a Mouse Writhing Assay

Matter No.: 14184-043001
Applicant(s): Mark G. Currie et al.
METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS



Figure 9: Competitive Radioligand Binding of MD-1100



Figure 10a: Minimum Systemic Absorption of MD-1100 (based on LCMS)



- **Limit of detection 0.00063 μg/mL (0.6 nM)**
- **Dosing at 10 mg/kg**

Figure 10b: Minimum Systemic Absorption of MD-1100 (based on ELISA)

Matter No.: 14184-043001
Applicant(s): Mark G. Currie et al.
METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS



* Limit of detection 0.061 µg/ml (40 nM)
Dosing at 10 mg/kg